Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE ...

Roche’s CT-996 showed 6.1% mean weight loss in just 4 weeks in obese patients without type 2 diabetes. Structure Therapeutics’ GSBR-1290 cut weight by 6.2% over 12 weeks in its Phase 2a ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral ...

Shares of Viking Therapeutics (VKTX) are up 13% to $25.17 in early trading while Structure Therapeutics (GPCR) is up 7% to 17.02. Discover outperforming stocks and invest smarter with Top Smart ...

Structure is now in line to become the second small molecule oral to enter the market and Viking becomes an “even more attractive partnership candidate,” the analyst tells investors in a ...

Granted, like Viking, Structure is not yet a profitable company. But at a $1 billion market cap, it's less than half the cost of Viking stock -- and apparently closer to market as well!

Viking Therapeutics moves toward the head of the pack to become No. 3, but Structure Therapeutics still has a lead in this race. Early this morning, Pfizer announced it will discontinue ...